<< Trauma center at SLU Hospital verified as Level 1 Trauma Center by ACSCOT | Variants in CRP gene not associated with increased risk of cancer >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

Proteostasis Therapeutics enters into exclusive license agreement with New York University

Published on January 8, 2010 at 2:22 AM · No Comments

Proteostasis Therapeutics announced today that it has entered into an exclusive license agreement with New York University for intellectual property related to discoveries from the laboratory of David Ron, M.D., Professor of Medicine and Julius Raynes Professor of Cell Biology at NYU Langone Medical Center’s Skirball Institute of Biomolecular Medicine. Dr. Ron’s research focuses on the Unfolded Protein Response (UPR) and his laboratory identifies new components of the cellular response to stress, which is the mechanism behind many common diseases of aging. The UPR is an important part of the Proteostasis Network (PN), the cellular machinery that maintains protein health. The exclusive license accelerates the Company’s drug discovery efforts to identify Proteostasis Regulators (PRs), small molecule drugs designed to restore protein balance. In addition, Dr. Ron has joined the Company’s Scientific Advisory Board.

“Our lab is focused on uncovering new components of the cellular stress response and understanding their role in the pathology of human diseases”

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading